아래와 같이 Takara Bio USA가 Jumpcode Genomics 와의 특허 소송에서 승리하였음을 알려드립니다.
Takara Bio USA Wins European Patent Challenge Filed by Jumpcode Genomics Over NGS Library Prep
February 15, 2022
NEW
YORK – Takara Bio USA mentioned on Tuesday that it has prevailed in a European
patent opposition initiated by Jumpcode Genomics.
The
agency mentioned the outcome confirms the validity of Takara’s European patent
3105325, titled “Methods of depleting a target molecule from an initial
collection of nucleic acids, and compositions and kits for practicing the
same.” This patent, granted in 2019, is a part of Takara’s portfolio masking
strategies utilized in its Smarter Stranded Total RNA-Seq and Smart-Seq Stranded
kits containing ZapR expertise.
“This
European patent represents an important part of the broad global intellectual
property that protects our innovative RNA-Seq product portfolio, so we are very
pleased with the outcome of the opposition proceedings, and that the Opposition
Division concurred with [us] regarding the validity and scope of the patent,”
Carol Lou, president and CEO of Takara Bio USA, mentioned in an announcement.
Jumpcode
challenged Takara’s IP in 2020 on the grounds of patentability in addition to
“formalities of the European Patent office,” Takara mentioned.
Jumpcode
didn’t instantly reply to a request for remark.
“Most
significantly, the … European Patent Office agreed with Takara Bio USA that
independent Claim 1, the broadest claim in the patent, is valid and should
therefore be maintained as originally granted,” the agency mentioned.
Takara Bio USA Wins EU Opposition Hearing on its Foundational NGS Library Enrichment Patent
SAN JOSE,
Calif.--(BUSINESS WIRE)--Feb 15, 2022
Takara Bio USA, Inc. (TBUSA) today announced that the European
Patent Office has reviewed and confirmed the validity of TBUSA’s granted
European patent EP 3105325, entitled “Methods of depleting a target molecule
from an initial collection of nucleic acids, and compositions and kits for
practicing the same.” TBUSA’s patent was opposed by Jumpcode Genomics, Inc.
The patent was challenged under multiple headings, relating both
to formalities of the European Patent Office and to the patentability of the
invention. Most significantly, the Opposition Division of the European Patent
Office agreed with TBUSA that independent Claim 1, the broadest claim in the
patent, is valid and should therefore be maintained as originally granted. The
claims of EP 3105325 relate to a method of selectively depleting cDNAs derived
from ribosomal RNAs (rRNA) from a sample either by cleavage or selectively
separating them from the sample through the use of nucleic acid guided
nucleases, such as CRISPR/Cas nucleases. The method of the invention thus
enables researchers to greatly improve the sensitivity of their RNA-Seq
libraries and achieve significantly more cost-effective sequencing results by
reducing the need to sequence unwanted abundant sequences derived from rRNA.
EP
3105325 forms part of TBUSA’s extensive global portfolio of granted and pending
patents covering the methods used in its SMARTer® Stranded Total RNA-Seq and SMART-Seq®
Stranded kits,
containing ZapR™ technology. These kits were developed to work with high- or
low-quality total RNA, do not require additional rRNA removal methods or kits,
and produce sequencing libraries that retain strand-of-origin information. The
integrated ZapR-based removal of rRNA-derived cDNAs—typically present in high abundance
following cDNA synthesis from total RNA inputs—makes these product workflows
extremely sensitive, yielding data that is highly reproducible with low mapping
to rRNA.
“This
European patent represents an important part of the broad global intellectual
property that protects our innovative RNA-Seq product portfolio, so we are very
pleased with the outcome of the opposition proceedings, and that the Opposition
Division concurred with TBUSA regarding the validity and scope of the patent,”
said Carol Lou, President and CEO of TBUSA.
About Takara Bio USA, Inc. Takara
Bio USA is
a wholly owned subsidiary of Takara Bio Inc. that manufactures and distributes
kits, reagents, and instruments for the life sciences, including NGS, PCR, gene
delivery, genome editing, stem cell research, nucleic acid and protein
purification, and automated sample preparation.
About Takara Bio Inc.Takara
Bio,
a world leader in biotechnology research and development, offers a host of life
science research solutions, from enzymes and GMP-grade reagents to contracted
cell and gene therapy manufacturing services and is the developer of the
RetroNectin reagent, a world standard in gene therapy protocols. Takara Bio is
committed to preventing disease and improving the quality of life for all
people through the use of biotechnology.
